Bridget Walton

Bridget Walton, MS, RAC, is an accomplished Regulatory Affairs executive with 20+ years’ experience leading global regulatory strategy in all phases of drug development and commercialization across therapeutic areas for leading pharmaceutical companies. Prior to joining MindMed, Ms. Walton held positions of increasing responsibility in Global Regulatory Affairs at Sunovion Pharmaceuticals Inc., where she led global regulatory strategy across a range of CNS disorders including schizophrenia, bipolar disorder, attention deficit hyperactivity disorder, binge eating disorder, and Parkinson’s disease psychosis.

Ms. Walton began her career as a molecular biologist, transitioning to a career in Regulatory Affairs for Wyeth Vaccines, Johnson & Johnson Pharmaceutical Research Division, and Novartis Pharmaceuticals Corporation.

Ms. Walton holds a Bachelor of Science degree in biology / chemistry / premed from Immaculata University, a Master of Science degree in molecular biology from Villanova University, and a Master of Science degree in Regulatory Affairs and Quality Assurance from Temple University School of Pharmacy. She is currently pursuing a doctorate degree in Regulatory Science at the

University of Southern California School of Pharmacy.